Association of Proton Pump Inhibitors with Hepatic Encephalopathy among Patients with Liver Cirrhosis

Abstract

Objective: To find an association between PPIs and increased risk of hepatic encephalopathy in cirrhosis.

Study Design: Case-Control study

Place and Duration of Study: This study was conducted at the conducted in the department of Medicine and gastroenterology, Ayub Teaching Hospital; Abbottabad from August 2019 to June 2020 for a period of 10 months. 

Materials and Methods: All patients with liver cirrhosis and hepatic encephalopathy presenting to the department of medicine and gastroenterology were included through a non-probability consecutive sampling.

Results: A total of 166 patients with liver cirrhosis were enrolled in the study including 93 (56.0%) male and 73 (44.0%) female patients. The mean age of the patients was 59.00±9.789 years. A total of103(62.0%) patients were found PPIs users and 63(38.0%) were found PPI nonusers. Patients using PPIs were 4 times more likely to develop Hepatic Encephalopathy as compared to those patients of liver cirrhosis who were not using PPIs (OR= 4.276, CI= 2.172-8.420).

Conclusion: Patients with liver cirrhosis who are using proton pump inhibitors are more likely to develop hepatic encephalopathy when compared to the control group.